Physician profile
Perry C Cook
NPI 1336140581
$803,242.13
in general payments reported to CMS, 2019-2025
31 companies · $43K in 2025
The $43K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291K · 2020: $77K · 2021: $87K · 2022: $148K · 2023: $91K · 2024: $67K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Travel and Lodging: $25K · Consulting Fee: $21K · Food and Beverage: $6,258 · Honoraria: $2,503.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,133.75 |
| Travel and Lodging | $24,560.01 |
| Consulting Fee | $20,605.50 |
| Food and Beverage | $6,257.50 |
| Honoraria | $2,503.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $243,650.50 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| Pharmacyclics LLC, An Abbvie Company | $112,161.50 | 2019-2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $65,536.66 | 2021-2024 | Rezlidhia, Tavalisse |
| Celgene Corporation | $63,897.43 | 2019-2025 | Reblozyl |
| Beigene USA, INC. | $56,466.05 | 2020-2025 | Brukinsa |
| Amgen INC. | $52,310.97 | 2019-2023 | Nplate, Kyprolis, Blincyto |
| Takeda Pharmaceuticals U.S.A., INC. | $33,077.87 | 2019-2025 | Ninlaro |
| E.R. Squibb & Sons, L.L.C. | $31,312.50 | 2019-2025 | Breyanzi, Pomalyst |
| Genzyme Corporation | $26,957.92 | 2020-2025 | |
| Verastem, INC. | $19,448.76 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15,481.35 | 2019-2022 | |
| Incyte Corporation | $15,441.16 | 2019 | |
| Epizyme, INC. | $12,874.28 | 2020-2021 | |
| Beone Medicines USA, INC. | $12,216.54 | 2025 | Brukinsa, Tevimbra |
| Novartis Pharmaceuticals Corporation | $10,565.47 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $9,917.90 | 2023 | Tazverik |
| Adc Therapeutics America, INC. | $8,597.69 | 2022-2023 | |
| Kite Pharma, INC. | $6,853.29 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $2,884.76 | 2019 | |
| Janssen Scientific Affairs, LLC | $2,300.00 | 2023 | |
| Pfizer INC. | $485.21 | 2019-2025 | |
| Glaxosmithkline, LLC. | $136.24 | 2025 | Ojjaara |
| Secura Bio, INC. | $132.12 | 2021-2024 | Copiktra |
| Abbvie INC. | $125.00 | 2023 | Epkinly |
| Merck Sharp & Dohme LLC | $125.00 | 2019 | |
| Genentech USA, INC. | $105.45 | 2019 | |
| Apellis Pharmaceuticals, INC. | $101.50 | 2023 | Empaveli |
| Daiichi Sankyo INC. | $29.24 | 2022 | |
| Lilly USA, LLC | $19.60 | 2019 | |
| Taiho Oncology, INC. | $15.67 | 2024 | |
| Sanofi-Aventis U.S. LLC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Perry Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.